Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the stock. Despite broader market uncertainties, the company’s ...

With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial ...

I believe this is a reasonable expectation. In sum, orforglipron is expected to quickly become a major blockbuster for Eli Lilly. In Q4 and full year 2024, Eli Lilly reported revenue of ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY ... Lilly’s shares jumped 3.4% on Feb. 6 after the company reported Q4 2024 adjusted EPS of $5.32 and revenue of $13.5 billion ...

Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

ELI LILLY ($LLY) is expected to release its quarterly earnings data on Thursday, May 1st before market open, per Finnhub. Analysts are expecting revenue of ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Looking ahead, Wall Street forecasts adjusted EPS of $23.21 for fiscal 2025, representing a 78.7% increase from $12.99 in ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker ... It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes in the first half of 2026.